Skip to content

Released May 8, 2014, after the close

10-Q filed May 8, 2014, 38 days after period end · 0001144204-14-028653

Q1 2014 · 10-Q
Revenue$6.70M+87.7% vs Q1 2013no prior Q4 2013 on file
Net Income-$7.35MN/M vs Q1 2013N/M vs Q4 2013
EPS Diluted$0.08+60.0% vs Q1 2013no prior Q4 2013 on file
Gross Profit$3,310,000+10.4%
Operating Income-$6,468,000N/M
Operating Cash Flow-$8,340,000N/M
Free Cash Flowderived-$8,603,000N/M
Margins · derived
Gross margin49.4%−34.6 pt vs Q1 2013
Operating margin-96.6%+27.5 pt vs Q1 2013
Net margin-109.7%+11.4 pt vs Q1 2013

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2014Q1 2013Q1 2012Q1 2011
Revenue$6.70M$3.57M$3.86M—
Net Income-$7.35M-$4.32M-$5.90M-$5.05M
EPS Diluted$0.08$0.05$0.07$0.06

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR